NASDAQ:PODDInsulet Stock Price, Forecast & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PODD stock has increased by 7.8% and is now trading at $185.54. View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 10 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) released its earnings results on Thursday, May, 7th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01. The medical instruments supplier earned $198 million during the quarter, compared to analyst estimates of $189.61 million. Insulet had a net margin of 0.66% and a return on equity of 7.66%. The firm's quarterly revenue was up 23.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.07 EPS. View Insulet's earnings history.

Insulet updated its second quarter 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $210.792-217.877 million, compared to the consensus revenue estimate of $201.99 million.

20 brokerages have issued 12 month price objectives for Insulet's shares. Their forecasts range from $100.00 to $250.00. On average, they anticipate Insulet's share price to reach $189.00 in the next twelve months. This suggests a possible upside of 1.9% from the stock's current price. View analysts' price targets for Insulet.

Headlines about PODD stock have been trending very positive recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Insulet earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutInsulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Adobe (ADBE), salesforce.com (CRM), Shopify (SHOP), Teladoc Health (TDOC) and Alteryx (AYX).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (10.96%), Capital World Investors (8.63%), Wellington Management Group LLP (4.27%), Primecap Management Co. CA (3.34%), Clearbridge Investments LLC (2.45%) and Fred Alger Management LLC (2.10%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Primecap Management Co. CA, William Blair Investment Management LLC, Lord Abbett & CO. LLC, Invesco Ltd., Federated Hermes Inc., Fred Alger Management LLC, and Waddell & Reed Financial Inc.. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, John A Fallon, Michael P Spears, and Shacey Petrovic. View insider buying and selling activity for Insulet.

PODD stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Carillon Tower Advisers Inc., Fisher Asset Management LLC, Capital Research Global Investors, Wellington Management Group LLP, Scout Investments Inc., Sumitomo Mitsui Trust Holdings Inc., and Perceptive Advisors LLC. View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $185.54.

Insulet has a market capitalization of $11.70 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]